AIM
CBAY

Alambic Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

Alambic Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-56,299
Closed -$196K – 166
2020
Q2 		$196K Sell
56,299
-59,246
-51% -$171K 0.49% 98
2020
Q1 		$171K Sell
115,545
-52,294
-31% -$87.8K 0.41% 95
2019
Q4 		$329K Buy
+167,839
New +$630K 0.28% 154

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Alambic Investment Management's CBAY Position: Q3 2020 in Review

Alambic Investment Management sold out of Cymabay Therapeutics (CBAY) in Q3 2020, closing a stake of 56,299 shares — an estimated $196K sold.

Alambic Investment Management first reported a position in CBAY in Q4 2019 and held it in 3 quarters. The position peaked at $329K in Q4 2019. 120 funds tracked by Wall St. Rank hold CBAY as of Q3 2020.

  • Alambic Investment Management reported no remaining Cymabay Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Alambic Investment Management sold 56,299 Cymabay Therapeutics shares in Q3 2020, an estimated $196K.
  • Alambic Investment Management first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 3 quarters.
  • Alambic Investment Management's Cymabay Therapeutics position peaked at $329K in Q4 2019.
  • 120 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2020.

Based on Alambic Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.